A Study of Trastuzumab in Combination With TS-ONE and Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified May 2011 by National University Hospital, Singapore.
Recruitment status was Recruiting
Information provided by:
National University Hospital, Singapore
First received: October 21, 2010
Last updated: May 23, 2011
Last verified: May 2011
The investigators hypothesis is that the combination of TS-ONE with cisplatin and trastuzumab is safe and as effective as combination treatment for HER2 positive gastric cancer.
Drug: Trastuzumab in Combination with TS-ONE and cisplatin
Endpoint Classification: Efficacy Study
Primary Purpose: Treatment
| Estimated Enrollment:
| Study Start Date:
| Estimated Primary Completion Date:
||December 2011 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||21 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patients with histologically proved adenocarcinoma of advanced gastric cancer.
- Patients who have HER2-positive cancer confirmed with IHC and/or FISH.
- Patients with proved presence of measurable (RECIST criteria) lesions within 28 days before enrollment.
- Patients without prior treatment (ex. radiotherapy, chemotherapy, hormonal therapy): Patients who completed adjuvant chemotherapy more than 180 days before may be enrolled but those who received TS-ONE or cisplatin shall be excluded.
- Patients with the following function of bone marrow, liver and kidney based on the laboratory tests measured within 14 days before enrollment. Hemoglobin >= 8.0 g/dL leukocytes >=3,000/mcL absolute neutrophil count >=1,500/mcL platelets >=100,000/mcL total bilirubin within normal institutional limits AST(SGOT)/ALT(SGPT)=<2.5 X institutional upper limit of normal ALP < twice of the upper limit of normal, creatinine within normal institutional limits or creatinine clearance >=60 mL/min for patients with creatinine levels above institutional normal (When AST(GOT), ALT(GPT) and ALP do not satisfy the conditions above and these values are considered to be caused by cancer, the decision is based on the discretion of investigators or co-investigators) Creatinine clearance can be estimated using Cockcroft-Gault formula man: Ccr (mL/min) = body weight (kg) x (140 - age)/(72 x serum creatinine (mg/dL)), woman: Ccr = male Ccr x 0.85].
- ECOG performance status =<2 (Karnofsky >60%; see Appendix A).
- Patients who are expected to survive more than 3 months after enrollment.
- Age >= 21.
- Patients of adequate oral intake.
- Patients who underwent electrocardiography within 28 days before enrollment.\
- Patients who give written informed consent for additional endoscopy to obtain fresh frozen tissue biopsies for translational studies at 2 time points pre-1st cycle of chemotherapy and at progression.
- Patients who give written informed consent for enrollment into trial.
- Patients for whom TS-ONE or cisplatin or trastuzumab is contraindicated.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to TS-ONE, cisplatin and trastuzumab.
- Patients receiving any other investigational agents.
- Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Baseline heart function LVEF (Left Ventricular Ejection Fraction) < 50%.
- Patients with serious (ex. inpatient care is needed) complications (ex. intestinal paralysis, intestinal occlusion, interstitial pneumonia or pulmonary fibrosis, poorly-controlled diabetes, renal failure or hepatic cirrhosis).
- Patients with massive ascites (moderate or higher, beyond the pelvic cavity and retention on the anterior surface of the liver on CT) or pleural effusion retention.
- Patients with extensive bone metastasis.
- Patients with known brain metastases.
- Patients with fresh bleeding from the digestive tract which needs repeated blood transfusion.
- Patients with diarrhea (4 or more times per day or watery diarrhea).
- Patients with simultaneously active multiple cancer.
- Pregnant or lactating female.
- Patients with reproductive potential who refuse to use an adequate means of contraception (including male patients).
- Other patients evaluated to be inadequate to participate in the study by co-investigators.
- No informed consent for either treatment regimen or collection of fresh frozen biopsy tissue for translational studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01228045
|National University Hospital
|Singapore, Singapore |
|Contact: Wei Peng Yong, MRCP, MB ChB 65 6772 4670 Wei_Peng_Yong@nuhs.edu.sg |
National University Hospital, Singapore
Coussens L, Yang-Feng TL, Liao YC, Chen E, Gray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science. 1985 Dec 6;230(4730):1132-9.
Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphin W, Sliwkowski M, Akita R, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res. 1993 Oct 15;53(20):4960-70.
History of Changes
|Other Study ID Numbers:
|Study First Received:
||October 21, 2010
||May 23, 2011
||Singapore: Domain Specific Review Boards
Keywords provided by National University Hospital, Singapore:
Patients with histologically proved adenocarcinoma of advanced gastric cancer
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on December 04, 2013
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Physiological Effects of Drugs